{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:43:36Z","timestamp":1791776616528,"version":"4.3.4"},"reference-count":30,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Up to a third of patients with hemato-oncologic conditions who have received multiply transfusions develop immune-mediated platelet transfusion refractoriness. Yet factors that influence posttransfusion platelet corrected count increments (CCI) in patients with HLA-alloimmune platelet transfusion refractoriness remain less well elucidated. Recent advances in HLA antibody characterization using fluorescent bead-based platforms enable the study of donor-specific antibody (DSA) avidity (as measured by mean fluorescence intensity [MFI]) and its impact on HLA-alloimmune platelet transfusion refractoriness. In this large retrospective study of 2012 platelet transfusions among 73 HLA-alloimmunized patients, we evaluated the impact of cumulative HLA DSA-MFI alongside other donor, platelet component, and patient characteristics on CCI at 2 and 24 hours after transfusion. As part of a quality improvement initiative, we also developed and tested a computerized algorithm to optimize donor\u2013recipient histocompatibility based on cumulative DSA-MFI and sought other actionable predictors of CCI. In multivariate analyses, cumulative HLA DSA-MFI of \u226510\u2009000, major\/bidirectional ABO-mismatch, splenomegaly, transfusion reactions, and platelet storage in additive solution negatively affected 2-hour but not 24-hour posttransfusion CCI. The DSA-MFI threshold of 10\u2009000 was corroborated by greater antibody-mediated complement activation and significantly more CCI failures above this threshold, suggesting the usefulness of this value to inform \u201cpermissive platelet mismatching\u201d and to optimize CCI. Furthermore, DSA-MFI decreases were deemed feasible by the computer-based algorithm for HLA-platelet selection in a pilot cohort of 8 patients (122 transfusions) evaluated before and after algorithm implementation. When HLA-selected platelets are unavailable, ABO-identical\/minor-mismatched platelet concentrates may enhance 2-hour CCI in heavily HLA-alloimmunized patients with platelet transfusion refractoriness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014143","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T20:12:05Z","timestamp":1721419925000},"page":"4689-4699","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-7809","authenticated-orcid":false,"given":"Aaron B.","family":"Boothby","sequence":"first","affiliation":[{"name":"1Department of Hematology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-4321","authenticated-orcid":false,"given":"Matthew K.","family":"Tanner","sequence":"additional","affiliation":[{"name":"2Internal Medicine Residency, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alswied","sequence":"additional","affiliation":[{"name":"3Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Youngs","sequence":"additional","affiliation":[{"name":"4Bloodworks Northwest, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Bribiesca Rodriguez","sequence":"additional","affiliation":[{"name":"5School of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thejaswi","family":"Bikkani","sequence":"additional","affiliation":[{"name":"6Medical Student Volunteer Program, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri","family":"Cha","sequence":"additional","affiliation":[{"name":"3Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Gernsheimer","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, University of Washington, Seattle, WA"},{"name":"8Division of Hematology\/Oncology, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-352X","authenticated-orcid":false,"given":"Idoia","family":"Gimferrer","sequence":"additional","affiliation":[{"name":"4Bloodworks Northwest, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Hess","sequence":"additional","affiliation":[{"name":"9Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9895-5176","authenticated-orcid":false,"given":"Lauge","family":"Sokol-Hessner","sequence":"additional","affiliation":[{"name":"10Medicine Center for Scholarship in Patient Care Quality and Safety, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Marivada","sequence":"additional","affiliation":[{"name":"11Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1950-5837","authenticated-orcid":false,"given":"Michael G.","family":"Nash","sequence":"additional","affiliation":[{"name":"12Division of Statistical Support, Institute of Translational Health Science, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy A.","family":"Flegel","sequence":"additional","affiliation":[{"name":"3Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8754-047X","authenticated-orcid":false,"given":"Ralph R.","family":"Vassallo","sequence":"additional","affiliation":[{"name":"13Vitalant Medical Affairs, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Stroncek","sequence":"additional","affiliation":[{"name":"3Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5723-7023","authenticated-orcid":false,"given":"Hamilton C.","family":"Tsang","sequence":"additional","affiliation":[{"name":"9Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya R.","family":"Panch","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, University of Washington, Seattle, WA"},{"name":"8Division of Hematology\/Oncology, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"3","key":"2024090915351588800_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2008.07189.x","article-title":"Platelet transfusion refractoriness","volume":"142","author":"Hod","year":"2008","journal-title":"Br J Haematol"},{"issue":"22","key":"2024090915351588800_bib2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJM196911272812202","article-title":"Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing","volume":"281","author":"Yankee","year":"1969","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024090915351588800_bib3","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1046\/j.1537-2995.2000.40121446.x","article-title":"Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity","volume":"40","author":"Petz","year":"2000","journal-title":"Transfusion"},{"issue":"4","key":"2024090915351588800_bib4","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/trf.12395","article-title":"Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review","volume":"54","author":"Vassallo","year":"2014","journal-title":"Transfusion"},{"issue":"3","key":"2024090915351588800_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.2830020303","article-title":"Successful transfusion of platelets \"mismatched\" for HLA antigens to alloimmunized thrombocytopenic patients","volume":"2","author":"Duquesnoy","year":"1977","journal-title":"Am J Hematol"},{"issue":"3","key":"2024090915351588800_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.2020007199","article-title":"An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial","volume":"137","author":"Marsh","year":"2021","journal-title":"Blood"},{"issue":"suppl 5","key":"2024090915351588800_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/tme.12409","article-title":"HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets","volume":"27","author":"O'Rafferty","year":"2017","journal-title":"Transfus Med"},{"issue":"10","key":"2024090915351588800_bib8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.5858\/arpa.2021-0051-OA","article-title":"Use of human leukocyte antigen (HLA)-incompatible platelet units in HLA platelet-refractory patients with limited number of or low-level HLA donor-specific antibodies results in permissive transfusions","volume":"146","author":"Sullivan","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"2024090915351588800_bib9","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1111\/trf.16430","article-title":"Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets","volume":"61","author":"Karafin","year":"2021","journal-title":"Transfusion"},{"issue":"3","key":"2024090915351588800_bib10","first-page":"200","article-title":"Relative importance of immune and non-immune causes of platelet refractoriness","volume":"66","author":"Doughty","year":"1994","journal-title":"Vox Sang"},{"issue":"1","key":"2024090915351588800_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/trf.16747","article-title":"Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: an updated view during a pandemic","volume":"62","author":"Escolar","year":"2022","journal-title":"Transfusion"},{"issue":"17","key":"2024090915351588800_bib12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"7-8","key":"2024090915351588800_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.humimm.2017.05.007","article-title":"Understanding solid-phase HLA antibody assays and the value of MFI","volume":"78","author":"Sullivan","year":"2017","journal-title":"Hum Immunol"},{"issue":"3","key":"2024090915351588800_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/trf.15108","article-title":"HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience","volume":"59","author":"Karlstr\u00f6m","year":"2019","journal-title":"Transfusion"},{"issue":"3","key":"2024090915351588800_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/vox.13565","article-title":"Virtual platelet cross-matching as transfusion management for patients with immune platelet refractoriness","volume":"119","author":"Bonet-Bub","year":"2024","journal-title":"Vox Sang"},{"issue":"4","key":"2024090915351588800_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1537-2995.1984.24484275566.x","article-title":"Plateletapheresis program. II. Computer selection of HLA compatible donors","volume":"24","author":"Jorgensen","year":"1984","journal-title":"Transfusion"},{"issue":"4","key":"2024090915351588800_bib17","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood-2004-10-4080","article-title":"HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients","volume":"107","author":"Nambiar","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"2024090915351588800_bib18","doi-asserted-by":"crossref","first-page":"8566","DOI":"10.1182\/blood-2022-170886","article-title":"Serial HLA-antibody testing identifies waning calculated panel reactive antibodies (cPRA) in platelet transfusion refractory patients with hematologic malignancies","volume":"140","author":"Parmar","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2024090915351588800_bib19","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood.V81.2.538.538","article-title":"Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates","volume":"81","author":"Atlas","year":"1993","journal-title":"Blood"},{"issue":"2","key":"2024090915351588800_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.tmrv.2010.11.002","article-title":"Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products","volume":"25","author":"Slichter","year":"2011","journal-title":"Transfus Med Rev"},{"issue":"7","key":"2024090915351588800_bib21","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1172\/JCI90597","article-title":"Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies","volume":"127","author":"Valenzuela","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2024090915351588800_bib22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjh.12890","article-title":"Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation","volume":"166","author":"Fasano","year":"2014","journal-title":"Br J Haematol"},{"key":"2024090915351588800_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"2024090915351588800_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2017-07-799270","article-title":"Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization","volume":"131","author":"Saris","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2024090915351588800_bib25","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1182\/blood-2011-11-393165","article-title":"The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia","volume":"119","author":"Triulzi","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2024090915351588800_bib26","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/j.1537-2995.2009.02273.x","article-title":"ABO-identical versus nonidentical platelet transfusion: a systematic review","volume":"49","author":"Shehata","year":"2009","journal-title":"Transfusion"},{"issue":"5","key":"2024090915351588800_bib27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/trf.16314","article-title":"Accidental massive platelet transfusion","volume":"61","author":"Tsang","year":"2021","journal-title":"Transfusion"},{"issue":"6","key":"2024090915351588800_bib28","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/trf.12498","article-title":"The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME)","volume":"54","author":"Tobian","year":"2014","journal-title":"Transfusion"},{"issue":"2","key":"2024090915351588800_bib29","first-page":"157","article-title":"Platelet concentrates in platelet additive solutions generate less complement activation products during storage than platelets stored in plasma","volume":"21","author":"de Wit","year":"2023","journal-title":"Blood Transfus"},{"issue":"3","key":"2024090915351588800_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/vox.12411","article-title":"Clinical and laboratory correlates of platelet\u00a0alloimmunization and refractoriness in the PLADO trial","volume":"111","author":"Hess","year":"2016","journal-title":"Vox Sang"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4689\/2241124\/blooda_adv-2024-014143-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4689\/2241124\/blooda_adv-2024-014143-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T15:35:47Z","timestamp":1725896147000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4689\/517116\/Cumulative-donor-specific-antibody-threshold"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":30,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014143","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}